Stifel maintains Buy on Iovance stock with $21 target On Monday, Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) yesterday. The company’s shares closed yesterday at $5.91. Discover outperforming ...